Abeo-HHC acetate

Last updated
Abeo-HHC acetate
Abeo-HHC-acetate structure.png
Identifiers
  • [(6aR,11aR)-6,6-dimethyl-3-pentyl-6a,7,8,10,11,11a-hexahydrocyclohepta[c]chromen-1-yl] acetate
CAS Number
Chemical and physical data
Formula C23H34O3
Molar mass 358.522 g·mol−1
3D model (JSmol)
  • CC(=O)Oc1cc(CCCCC)cc2OC(C)(C)[C@@H]3CCCCC[C@H]3c12
  • InChI=1S/C23H34O3/c1-5-6-8-11-17-14-20(25-16(2)24)22-18-12-9-7-10-13-19(18)23(3,4)26-21(22)15-17/h14-15,18-19H,5-13H2,1-4H3/t18-,19-/m1/s1
  • Key:NTJCIGWEPIAFSM-RTBURBONSA-N

Abeo-HHC acetate is a semi-synthetic derivative of tetrahydrocannabinol, first described in the 1980s. It is synthesised from delta-11-tetrahydrocannabinol, which can be made to undergo a ring expansion reaction via a hydrazone intermediate. [1] [2] It is structurally similar to HHC-acetate except it's substituted with a cycloheptyl ring instead of a methylated cyclohexyl ring.

See also

Related Research Articles

<span class="mw-page-title-main">THC-O-acetate</span> Acetate ester of tetrahydrocannabinol (THC)

THC-O-acetate is the acetate ester of THC. The term THC-O-acetate and its variations are commonly used for two types of the substance, dependent on which cannabinoid it is synthesized from. The difference between Δ8-THC and Δ9-THC is bond placement on the cyclohexene ring.

<span class="mw-page-title-main">Dimethylheptylpyran</span> Chemical compound

Dimethylheptylpyran is a synthetic analog of THC, which was invented in 1949 during attempts to elucidate the structure of Δ9-THC, one of the active components of Cannabis. DMHP is a pale yellow, viscous oil which is insoluble in water but dissolves in alcohol or non-polar solvents.

<span class="mw-page-title-main">9-Nor-9β-hydroxyhexahydrocannabinol</span> Chemical compound

9-Nor-9β-hydroxyhexahydrocannabinol is a cannabinoid first discovered from early modifications to the structure of THC, in a search for the simplest compound that could still fulfill the binding requirements to produce cannabis-like activity.

<span class="mw-page-title-main">8,9-Dihydrocannabidiol</span> Chemical compound

8,9-Dihydrocannabidiol is a synthetic cannabinoid that is closely related to cannabidiol (CBD) itself. that was first synthesized by Alexander R. Todd in 1940 derived from the catalytic hydrogenation of cannabidiol.

<span class="mw-page-title-main">Δ-8-Tetrahydrocannabinol</span> Isomer of tetrahydrocannabinol

Δ-8-tetrahydrocannabinol is a psychoactive cannabinoid found in the Cannabis plant. It is an isomer of delta-9-tetrahydrocannabinol, the compound commonly known as THC, with which it co-occurs in hemp; natural quantities of ∆8-THC found in hemp are low.

<span class="mw-page-title-main">Δ-3-Tetrahydrocannabinol</span> Chemical compound

Δ-3-Tetrahydrocannabinol is a synthetic isomer of tetrahydrocannabinol, developed during the original research in the 1940s to develop synthetic routes to the natural products Δ8-THC and Δ9-THC found in the cannabis plant. While the normal trans configuration of THC is in this case flattened by the double bond, it still has two enantiomers as the 9-methyl group can exist in an (R) or (S) conformation. The (S) enantiomer has similar effects to Δ9-THC though with several times lower potency, while the (R) enantiomer is many times less active or inactive, depending on the assay used. It has been identified as a component of vaping liquid products.

<span class="mw-page-title-main">Δ-7-Tetrahydrocannabinol</span> Chemical compound

Δ-7-Tetrahydrocannabinol is a synthetic isomer of tetrahydrocannabinol. The (6aR,9S,10aR)-Δ7-THC epimer is only slightly less potent than Δ9-THC itself, while the (9R) enantiomer is much less potent.

<span class="mw-page-title-main">Δ-10-Tetrahydrocannabinol</span> Isomer of tetrahydrocannabinol

Δ-10-Tetrahydrocannabinol is a positional isomer of tetrahydrocannabinol, discovered in the 1980s. Two enantiomers have been reported in the literature, with the 9-methyl group in either the (R) or (S) conformation; of these, the (R) enantiomer appears to be the more active isomer as well as the double bond in the 10th position instead of the 9th maintaining about 30 to 40 percent the potency of delta-9-THC. Δ10-THC has rarely been reported as a trace component of natural cannabis, though it is thought to be a degradation product similar to cannabinol rather than being produced by the plant directly. However, it is found more commonly as an impurity in synthetic delta-8-THC produced from cannabidiol and can also be synthesized directly from delta-9-THC.

<span class="mw-page-title-main">Hexahydrocannabinol</span> Hydrogenated derivative of THC

Hexahydrocannabinol (HHC) is a hydrogenated derivative of tetrahydrocannabinol (THC). It is a naturally occurring phytocannabinoid that has rarely been identified as a trace component in Cannabis sativa, but can also be produced synthetically by acid cyclization and hydrogenation of cannabidiol. The synthesis and bioactivity of HHC was first reported in 1940 by Roger Adams.

<span class="mw-page-title-main">11-Hydroxy-Delta-8-THC</span> Metabolite of delta-8-THC

11-Hydroxy-Delta-8-tetrahydrocannabinol is an active metabolite of Δ8-THC, a psychoactive cannabinoid found in small amounts in cannabis. It is an isomer of 11-OH-Δ9-THC, and is produced via the same metabolic pathway. It was the first cannabinoid metabolite discovered in 1970.

<span class="mw-page-title-main">9-Hydroxyhexahydrocannabinol</span> Synthetic cannabinoid

9-Hydroxyhexahydrocannabinol (9-OH-HHC) is a semi-synthetic derivative of tetrahydrocannabinol. It is formed as an impurity in the synthesis of Delta-8-THC, and retains activity in animal studies though with only around 1/10 the potency of Δ9-THC, with the 9α- and 9β- enantiomers having around the same potency.

<span class="mw-page-title-main">11-Hydroxyhexahydrocannabinol</span> Chemical compound

11-Hydroxyhexahydrocannabinol is an active metabolite of tetrahydrocannabinol (THC) and a metabolite of the trace cannabinoid hexahydrocannabinol (HHC).

<span class="mw-page-title-main">JWH-138</span> Chemical compound

JWH-138 (THC-Octyl, Δ8-THC-C8) is a synthetic cannabinoid first synthesised by John W. Huffman, with a Ki of 8.5nM at the CB1 cannabinoid receptor. THC-Octyl and its hydrogenated analog HHC-Octyl was synthesized and studied by Roger Adams as early as 1942.

<span class="mw-page-title-main">8-Hydroxyhexahydrocannabinol</span> Cannabinoid metabolite

8-Hydroxyhexahydrocannabinols are active primary metabolites of hexahydrocannabinol (HHC) in animals and trace phytocannabinoids. The 8-OH-HHCs are produced in notable concentrations following HHC administration in several animal species, including humans. They have drawn research interest for their role in HHC toxicology and stereoisomeric probes of the cannabinoid drug/receptor interaction.

<span class="mw-page-title-main">Delta-11-Tetrahydrocannabinol</span> Isomer of tetrahydrocannabinol

Delta-11-Tetrahydrocannabinol is a rare isomer of tetrahydrocannabinol, developed in the 1970s. It can be synthesised from Δ8-THC by several different routes, though only the enantiomer is known. In recent studies in 2022 it was found to "significantly reduce" the effects of Δ9-THC and has been suggested as antagonist of the CB1 receptor in humans, with the cited study showing "one partial success in the quest for an antagonist is the fact that D9,11-THC was found to significantly reduce the effect of D9-THC." and did not substitute for THC in rhesus monkeys. It has been identified as a component of grey market vaping liquids sold for use in humans.

<span class="mw-page-title-main">HHC-acetate</span> Semi-synthetic cannabinoid derivative drug

HHC-acetate is a semi-synthetic cannabinoid derivative which has been marketed since around 2022. It is believed to be made in a three step process from cannabidiol extracted from hemp. The legal status of hexahydrocannabinol and derivatives such as HHC-O varies between countries leading to widespread sale in some jurisdictions in Europe and the US, but in France HHC and HHC-O were banned in 2023, and HHC is already banned in several other countries. On 1st of March 2024 HHC was banned on Czech Republic.

<span class="mw-page-title-main">Hexahydrocannabiphorol</span> Semisythetic cannabinoid derivative drug

Hexahydrocannabiphorol is a semi-synthetic cannabinoid derivative which has been marketed since around 2021. It is believed to be made from the hydrogenation of tetrahydrocannabiphorol (THCP). THCP is only reported as a trace component of cannabis in 2019. HHCP was studied by Roger Adams as early as 1942.

<span class="mw-page-title-main">Hexahydrocannabihexol</span> Semi-synthetic cannabinoid derivative drug

Hexahydrocannabihexol (HHCH) is a semi-synthetic cannabinoid derivative. It was first synthesised by Roger Adams in 1942 and found to be more potent than either the pentyl or heptyl homologues, or the unsaturated tetrahydrocannabinol analogue.

<span class="mw-page-title-main">HHCP-O-acetate</span> Semi-synthetic cannabinoid derivative drug

HHCP-O-acetate is a semi-synthetic derivative of tetrahydrocannabiphorol (THCP) derived in several steps by hydrogenation to hexahydrocannabiphorol (HHCP) followed by acetylation of the OH group. It has been found as a component of grey-market cannabis products such as e-cigarette liquids and edible gumdrops, and is allegedly a potent and long-lasting psychoactive cannabinoid.

<span class="mw-page-title-main">Isotetrahydrocannabinol</span> Phytocannabinoid compound

Isotetrahydrocannabinol (iso-THC) is a phytocannabinoid similar in structure to cannabicitran which has been identified as a trace component of Cannabis, but is more commonly found as an impurity in synthetic THC which has been made from cannabidiol, along with other isomers with the double bond in a different position and the saturated dihydro derivative. iso-THC can be described as the upper cyclization product of CBD, while THC is the lower cyclization product of CBD. Its pharmacology has not been studied, though it is commonly found as a trace impurity in commercially marketed Δ8-THC products.

References

  1. Srebnik M, Mechoulam R (1984). "Reactions of cannabinoid tosylhydrazones: Stereochemical aspects". Tetrahedron. 40 (19): 3839–3843. doi:10.1016/S0040-4020(01)88815-3.
  2. Ujváry I (June 2023). "Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review". Drug Testing and Analysis. doi:10.1002/dta.3519. PMID   37269160. S2CID   259046522.